Development of a CRISPR-Cas12a Assay for Detection of the P nimB G Mutation Associated with Heme-Dependent Metronidazole Resistance in Clostridioides difficile

This article has been Reviewed by the following groups

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Objective

Heme-dependent metronidazole (MTZ) resistance has emerged in Clostridioides difficile and is primarily mediated by a T-to-G single-nucleotide polymorphism (SNP) in the promoter of nimB (P nimB G ). We aimed to develop a CRISPR-Cas12a-based assay for rapid detection of the P nimB G mutation associated with MTZ resistance.

Methods

A series of primers and CRISPR RNAs (crRNAs) were designed and optimized to identify the most effective combination for discriminating between P nimB G (MTZ-resistant) and P nimB T (MTZ-susceptible) alleles. Detection was evaluated by visual fluorescence using blue-light and UV imaging systems, as well as by quantitative fluorescence measurements.

Results

The CRISPR-Cas12a assay accurately differentiated P nimB G and P nimB T alleles in C. difficile . In a collection of clinical isolates, the assay correctly identified all 11 MTZ-susceptible isolates carrying the P nimB T allele and all 10 MTZ-resistant isolates carrying the P nimB G allele. Fluorescence signals were readily detected both visually and quantitatively. Furthermore, colony PCR using crude colony lysates yielded results comparable to those obtained with purified genomic DNA, enabling rapid colony-based detection without conventional DNA extraction.

Conclusions

The CRISPR-Cas12a assay enables rapid molecular detection of the P nimB G mutation associated with heme-dependent MTZ resistance in C. difficile . This approach could complement conventional susceptibility testing for MTZ resistance detection.

Article activity feed